hrp0094p2-30 | Adrenals and HPA Axis | ESPE2021

Development of a novel weight-based steroid emergency plan for patients with Duchenne Muscular Dystrophy

Tollerfield Sally , Atterbury Abigail , Antell Hannah , Craig Sian , Smith Natalie , Sarkozy Anna , Manzur Adnan , Hoskins Steve , Amin Rakesh , Dattani Mehul , Katugampola Harshini ,

Background: Long-term glucocorticoid therapy with Prednisolone or Deflazacort has improved outcomes in patients with Duchenne Muscular Dystrophy (DMD), however recommended dosages suppress the hypothalamic-pituitary-adrenal axis, leading to adrenal insufficiency. All boys prescribed glucocorticoid therapy should be assumed to have adrenal suppression, and therefore at risk of adrenal crisis during illness or stress (eg. surgery, bisphosphonate infusions). The ...

hrp0095p1-529 | Growth and Syndromes | ESPE2022

A case of Silver Russell Syndrome-like phenotype with abnormal methylation of the imprinted GNAS locus (20q13)

Festa Adalgisa , Luongo Caterina , Aiello Francesca , Santoro Claudia , Piluso Giulio , Torella Annalaura , Del Vecchio Blanco Francesca , Nigro Vincenzo , Miraglia del Giudice Emanuele , Grandone Anna

Background: Silver Russell Syndrome (SRS) is characterized by pre- and postnatal growth failure, relative macrocephaly at birth, prominent forehead, feeding difficulties and body asymmetry. The diagnosis is clinical, the genetic mechanisms involved are different, in 50% of cases loss of methylation (LOM) at the paternal H19/IGF2:IG-DMR (chr11p15.5), in 10% of cases maternal uniparental disomy of chromosome 7 (UPD(7)mat), cases of maternal uniparental ...

hrp0095p1-121 | Growth and Syndromes | ESPE2022

Qatar National standards for newborn weight, length, and Abdominal and Head Circumference by gestational age and sex: A part of the Newborn Cross-Sectional Study of the INTERGROWTH-21st Project

length , Abdominal and Head Circumference by gestational age and sex: A part of the Newborn Cross-Sectional Study of the INTERGROWTH-21st Project and , Alyafei Fawzia , Soliman Ashraf , Alqubasi Mai , Olukade Tawa , Ali Hamdy , Alturk Mohamed , Alaaraj Nada , Hamed Noor , Ahmed Shayma

Introduction: This was a population-based retrospective data analysis. The study was part of the Vulnerable Newborn Study, approved by the Hamad Medical Corporation Institutional Review Board (IRB No MRC-01-21-277).Setting and Participants: The population for this analysis comprised of a 4-year cohort data (January 2016 to December 2019) for births conducted in all HMC hospitals (representing 90% of all births in the cou...

hrp0086fc10.3 | Perinatal Endocrinology | ESPE2016

Pharmacokinetics of Long Acting Somatostatin Analogue (Lanreotide) Therapy in Hyperinsulinaemic Hypoglycaemia (HH) and Understanding its Molecular Action via Somatostatin Receptors by Immunohistochemistry

Shah Pratik , Rahman Sofia , McElroy Sharon , Gilbert Clare , Morgan Kate , Hinchey Louise , Guemes Maria , Alam Syeda , Senniappan Senthil , Button Roberta , Margetts Rebecca , Levy Hannah , Santacreu Emma Bascompta , Marti Carles Morte , Lezcano Carles Celma , Amin Rakesh , Hussain Khalid

Background: Diazoxide and octreotide are first and second-line of treatment for HH respectively. Long-acting somatostatin analogue (Lanreotide, LA) has been used in adults with neuroendocrine conditions through its effect on somatostatin receptors 2 (SSTR2) and 5 (SSTR5).Objective and hypotheses: (i) To evaluate the efficacy, safety and pharmacokinetics of LA therapy in children with HH. (ii) To determine somatostatin receptor expression on pancreatic al...

hrp0082p1-d1-174 | Perinatal and Neonatal Endocrinology | ESPE2014

Use of Long Acting Somatostatin Analogue (Lanreotide) in Congenital Hyperinsulinism*

Shah Pratik , Gilbert Clare , Morgan Kate , Hinchey Louise , Levy Hannah , Button Roberta , Landy Niamh , Margetts Rebecca , Senniappan Senthil , Santacreu Emma Bascompta , Marti Carles Morte , Lezcano Carles Celma , Amin Rakesh , Hussain Khalid

Background: Congenital hyperinsulinism (CHI) is cause of severe hypoglycaemia. Octreotide (somatostatin analogue), given as four times daily s.c. injections or via a pump, is used as second line treatment in diazoxide unresponsive CHI patients.Objective and hypotheses: The aim of our study was to evaluate the use of a long acting somatostatin analogue (Lanreotide) in patients with CHI.Method: Diffuse CHI patients above three years ...

hrp0084p2-493 | Hypo | ESPE2015

Long Acting Somatostatin Analogue (Lanreotide) Therapy in Congenital Hyperinsulinism – Pharmacokinetics and Long-Term Follow-Up Study

Shah Pratik , Rahman Sofia , McElroy Sharon , Gilbert Clare , Morgan Kate , Hinchey Louise , Alam Syeda , Senniappan Senthil , Button Roberta , Margetts Rebecca , Levy Hannah , Marti Carles Morte , Lezcano Carles Celma , Santacreu Emma Bascompta , Amin Rakesh , Hussain Khalid

Background: Congenital hyperinsulinism (CHI) causes severe hypoglycaemia in children. Diazoxide and daily octreotide injections are first and second-line of treatment for CHI respectively. Diazoxide can cause severe hypertrichosis resulting in parental anxiety and compliance issues.Objective and hypotheses: To evaluate the efficacy, safety and pharmacokinetics of Lanreotide therapy in CHI patients.Method: Patients >6 months of ...

hrp0094p1-114 | Fat, Metabolism and Obesity B | ESPE2021

EuRRECa Registry Genetic Obesity Survey Results

Shaikh Guftar , Akker Erica van den , Bryce Jillian , Ali Salma , Amin Rakesh , Cools Martine , Dattani Mehul , Grugni Graziano , Khairi Ranna El , Persani Luca , Peters Catherine , Rossum Elisabeth van , Waele Kathleen De , Gan Hoong-Wei , Ahmed Faisal ,

Introduction: The diagnosis and treatment of patients with rare diseases is often difficult as most clinicians do not encounter them. Therefore, centralization and collaboration between centers of expertise is necessary. European Reference Networks (ERN’s) such as RareEndoERN provide a platform for this, with one of its main thematic groups having a specific focus on rare growth and obesity disorders. Genetic obesity encompasses a heterogeneous group of c...

hrp0094p1-170 | Growth B | ESPE2021

Facilitating Telehealth In A Tertiary Paediatric Endocrine Service: A Quality Improvement Initiative To Reduce The Discrepancy Between Parent-reported And Auxologist Height Measurements

McGlacken-Byrne Sinead M , Alexander Ashley , Tollerfield Sally , Atterbury Abigail , Antell Hannah , Mead Victor , Dastamani Antonia , Peters Catherine , Gan Hoong Wei , Amin Rakesh , Dattani Mehul T , Hoskins Steve , Katugampola Harshini ,

Background: The COVID-19 crisis required paediatric endocrinologists to rapidly adopt telehealth into their clinical practice. Accurate auxology is a cornerstone of paediatric endocrinology care and is needed to monitor growth and guide medication changes. Remote consultations depend upon parent-reported measurements. However, home height measurements are often inaccurate.Aim: We designed a quality improvement study with...

hrp0095p1-510 | Growth and Syndromes | ESPE2022

Temple syndrome: clinical findings and body composition

Juriaans Alicia , Kerkhof Gerthe , Hokken-Koelega Anita

Background/aims: Temple syndrome (TS14) is an imprinting disorder caused by maternal uniparental disomy of chromosome 14 (UPD(14)mat), paternal deletion of 14q32 or by an isolated methylation defect. TS14 is considered a Prader-Willi-like (PWL) disorder and phenotypic features include pre- and postnatal growth retardation, hypotonia, feeding difficulties, precocious puberty, short stature and truncal obesity.Methods: Thi...

hrp0082p1-d2-155 | Growth (1) | ESPE2014

Clinical Characteristics and Imprinting Analysis of Chinese Silver Russell Syndrome

Wu Di , Gong Chunxiu , Zhao Yang

Background: Silver Russell syndrome (SRS) is an imprinting defect disease.Objective: To study clinical characteristics and imprinting defects in Chinese children with SRS.Methods: Forty-nine SRS cases were studied retrospectively. Out of these 49 cases, 36 were available to be detected chromosome 11p15 imprinting defects and 21 cases were detected uniparental disomy of maternal chromosome 7 (UPD(7) mat).Resul...